Martin R C, Edwards M J, Wong S L, Tuttle T M, Carlson D J, Brown C M, Noyes R D, Glaser R L, Vennekotter D J, Turk P S, Tate P S, Sardi A, Cerrito P B, McMasters K M
Department of Surgery, Division of Surgical Oncology, James Graham Brown Cancer Center, and the Department of Mathematics, University of Louisville, KY 40202, USA.
Surgery. 2000 Aug;128(2):139-44. doi: 10.1067/msy.2000.108064.
Multiple radioactive lymph nodes are often removed during the course of sentinel lymph node (SLN) biopsy for breast cancer when both blue dye and radioactive colloid injection are used. Some of the less radioactive lymph nodes are second echelon nodes, not true SLNs. The purpose of this analysis was to determine whether harvesting these less radioactive nodes, in addition to the "hottest" SLNs, reduces the false-negative rate.
Patients were enrolled in this multicenter (121 surgeons) prospective, institutional review board-approved study after informed consent was obtained. Patients with clinical stage T1-2, N0, M0 invasive breast cancer were eligible. This analysis includes all patients who underwent axillary SLN biopsy with the use of an injection of both isosulfan blue dye and radioactive colloid. The protocol specified that all blue nodes and all nodes with 10% or more of the ex vivo count of the hottest node should be removed and designated SLNs. All patients underwent completion level I/II axillary dissection.
SLNs were identified in 672 of 758 patients (89%). Of the patients with SLNs identified, 403 patients (60%) had more than 1 SLN removed (mean, 1.96 SLN/patient) and 207 patients (31%) had nodal metastases. The use of filtered or unfiltered technetium sulfur colloid had no impact on the number of SLNs identified. Overall, 33% of histologically positive SLNs had no evidence of blue dye staining. Of those patients with multiple SLNs removed, histologically positive SLNs were found in 130 patients. In 15 of these 130 patients (11.5%), the hottest SLN was negative when a less radioactive node was positive for tumor. If only the hottest node had been removed, the false-negative rate would have been 13.0% versus 5.8% when all nodes with 10% or more of the ex vivo count of the hottest node were removed (P =.01).
These data support the policy that all blue nodes and all nodes with 10% or more of the ex vivo count of the hottest SLN should be harvested for optimal nodal staging.
在乳腺癌前哨淋巴结(SLN)活检过程中,若同时使用蓝色染料和放射性胶体注射,通常会切除多个放射性淋巴结。一些放射性较弱的淋巴结是二级淋巴结,并非真正的前哨淋巴结。本分析的目的是确定除了“最热点”的前哨淋巴结外,切除这些放射性较弱的淋巴结是否能降低假阴性率。
在获得知情同意后,患者被纳入这项多中心(121位外科医生)的前瞻性、经机构审查委员会批准的研究。临床分期为T1-2、N0、M0的浸润性乳腺癌患者符合条件。本分析包括所有使用异硫蓝染料和放射性胶体注射进行腋窝前哨淋巴结活检的患者。方案规定,所有蓝色淋巴结以及所有放射性计数达到最热点淋巴结体外计数10%或更多的淋巴结均应切除并指定为前哨淋巴结。所有患者均接受了I/II级腋窝清扫术。
758例患者中有672例(89%)发现了前哨淋巴结。在发现前哨淋巴结的患者中,403例(60%)切除了1个以上的前哨淋巴结(平均每位患者1.96个前哨淋巴结),207例(31%)有淋巴结转移。使用过滤或未过滤的锝硫胶体对发现的前哨淋巴结数量没有影响。总体而言,33%组织学阳性的前哨淋巴结没有蓝色染料染色的证据。在切除多个前哨淋巴结的患者中,130例发现了组织学阳性的前哨淋巴结。在这130例患者中的15例(11.5%)中,当一个放射性较弱的淋巴结肿瘤呈阳性时,最热点的前哨淋巴结为阴性。如果仅切除最热点的淋巴结,假阴性率将为13.0%,而当切除所有放射性计数达到最热点淋巴结体外计数10%或更多的淋巴结时,假阴性率为5.8%(P = 0.01)。
这些数据支持这样的策略,即应切除所有蓝色淋巴结以及所有放射性计数达到最热点前哨淋巴结体外计数10%或更多的淋巴结,以实现最佳的淋巴结分期。